Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Home›Research›Companies

Companies

Loading
Home›
Research›
Companies›
ArsenalBio
AddedFeb 13, 2024
UpdatedJun 18, 2026
ArsenalBio

ArsenalBio

Series B

US-based ArsenalBio innovates safe, effective cellular therapies primarily for cancer patients.

Founded
2019
Overview
Compare
Fundraising
Employees
Website

Founded in South San Francisco, ArsenalBio is dedicated to creating safe and effective cellular therapies for patients with chronic diseases, focusing initially on cancer. The company leverages a programmable and computationally driven approach to engineer advanced medical treatments. ArsenalBio's core mission is to improve patient outcomes through innovative cellular therapies, combining expertise from diverse scientific disciplines and clinical manufacturing.

Notable affiliates include a collective of experts across various scientific fields, contributing to ArsenalBio's pioneering work. The company has attracted significant attention from investors in the biotech sector, reflecting confidence in its potential. ArsenalBio's key achievements include advancements in cellular therapy technologies that promise to transform cancer treatment. The overall impact of ArsenalBio is marked by its commitment to enhancing the quality of life for patients through cutting-edge medical solutions.

ArsenalBio - Similar Companies

Cell BioEngines logo

Cell BioEngines

cellbioengines.com

Asher Bio logo

Asher Bio

asherbio.com

Celularity logo

Celularity

celularity.com

A2 Biotherapeutics logo

A2 Biotherapeutics

a2bio.com

Cellular Approaches logo

Cellular Approaches

Atara Biotherapeutics logo

Atara Biotherapeutics

atarabio.com

Outpace Bio logo

Outpace Bio

outpacebio.com

Cellerant Therapeutics logo

Cellerant Therapeutics

Lyell Immunopharma logo

Lyell Immunopharma

lyell.com

Kronos Bio logo

Kronos Bio

Be Biopharma logo

Be Biopharma

Legend Biotech logo

Legend Biotech

legendbiotech.com

Appia Bio logo

Appia Bio

appiabio.com

Alloplex Biotherapeutics logo

Alloplex Biotherapeutics

Iovance Biotherapeutics logo

Iovance Biotherapeutics

iovance.com

ArsenalBio - Quick Facts

Who are ArsenalBio's competitors?

Companies similar to ArsenalBio include Cell BioEngines, Asher Bio, Celularity and A2 Biotherapeutics.

When was ArsenalBio founded?

ArsenalBio was founded in 2019.

When was ArsenalBio's last funding round?

ArsenalBio's most recent funding round was for $220.8M (USD) in September 2022.

How much has ArsenalBio raised to-date?

As of Sep 6, 2022, ArsenalBio has raised a total of $305.8M (USD).

How many employees does ArsenalBio have?

ArsenalBio has 197 employees as of Feb 5, 2024.

ArsenalBio - Classification

Ownership
  • Equity
  • Venture Capital
Technology
  • Biotech
Geographic Exposure
  • United States
Revenue
  • Recurring
  • Software
Customer
  • Enterprise
Main Product
  • Cellular Therapies
Tags
  • Healthtech
NAICS
  • 540000Professional, Scientific, and Technical Services
  • 541714Research and Development in Biotechnology (except Nanobiotechnology)
  • 541000Professional, Scientific, and Technical Services
  • 541700Scientific Research and Development Services
  • 541710Research and Development in the Physical, Engineering, and Life Sciences
SIC
  • 8700Engineering, Accounting, Research, Management, And Related Services
  • 8730Research, Development, And Testing Services
  • 8731Commercial Physical and Biological Research
Show 5 more industry codes
NAICS
  • 620000Health Care and Social Assistance
  • 623000Nursing and Residential Care Facilities
SIC
  • 8000Health Services
  • 8040Offices And Clinics Of Other Health Practitioners
  • 8049Offices And Clinics Of Health Practitioners, Not Elsewhere Classified